Literature DB >> 21425240

Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.

Fabrizio Micheli1.   

Abstract

Dopamine (DA) D(3) receptor antagonism might play a significant role in different therapeutic areas. A high number of preclinical studies on DA D(3) receptor antagonists have shown efficacy in animal models of Parkinson's disease, schizophrenia and drug dependence. This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compounds. Both primary and patent literature is reviewed here. Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers. Examples of advanced leads from academia and industry are described. The latest potential therapeutic applications are reported too.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425240     DOI: 10.1002/cmdc.201000538

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  21 in total

1.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

Review 2.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

3.  Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores.

Authors:  Sean W Reilly; Suzy Griffin; Michelle Taylor; Kristoffer Sahlholm; Chi-Chang Weng; Kuiying Xu; Daniel A Jacome; Robert R Luedtke; Robert H Mach
Journal:  J Med Chem       Date:  2017-11-21       Impact factor: 7.446

Review 4.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

5.  Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.

Authors:  Amy Hauck Newman; Thijs Beuming; Ashwini K Banala; Prashant Donthamsetti; Katherine Pongetti; Alex LaBounty; Benjamin Levy; Jianjing Cao; Mayako Michino; Robert R Luedtke; Jonathan A Javitch; Lei Shi
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

6.  Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Jagan R Etukala; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2012-01-21       Impact factor: 3.641

Review 7.  Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Authors:  Amy Hauck Newman; Brandi L Blaylock; Michael A Nader; Jack Bergman; David R Sibley; Phil Skolnick
Journal:  Biochem Pharmacol       Date:  2012-07-03       Impact factor: 5.858

8.  Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.

Authors:  Vivek Kumar; Alessandro Bonifazi; Michael P Ellenberger; Thomas M Keck; Elie Pommier; Rana Rais; Barbara S Slusher; Eliot Gardner; Zhi-Bing You; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

9.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

10.  Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66.

Authors:  Vivek Kumar; Ashwini K Banala; Erick G Garcia; Jianjing Cao; Thomas M Keck; Alessandro Bonifazi; Jeffery R Deschamps; Amy Hauck Newman
Journal:  ACS Med Chem Lett       Date:  2014-03-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.